James and Joe's questions to Recursion Pharmaceuticals Inc (RXRX) leadership • Q1 2025
Question
James and Joe asked when Recursion might see a partner option-in a molecule candidate and what new levers within the Recursion OS could accelerate partnership programs.
Answer
Co-Founder and CEO Christopher Gibson highlighted that Sanofi has already optioned four programs and Roche Genentech has optioned one, with more potential for later-stage options. Chief R&D Officer Najat Khan detailed three acceleration levers: using multimodal clinical genomic data for better patient selection, advanced chemistry design to model drug-like properties earlier, and leveraging clin-tech capabilities during development.